Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
TEAR's Cash to Debt is ranked higher than
95% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. TEAR: No Debt )
TEAR' s 10-Year Cash to Debt Range
Min: 0.09   Max: No Debt
Current: No Debt

Equity to Asset 0.83
TEAR's Equity to Asset is ranked higher than
90% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. TEAR: 0.83 )
TEAR' s 10-Year Equity to Asset Range
Min: -1.1   Max: 0.96
Current: 0.83

-1.1
0.96
Interest Coverage No Debt
TEAR's Interest Coverage is ranked higher than
88% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.07 vs. TEAR: No Debt )
TEAR' s 10-Year Interest Coverage Range
Min: 2470.88   Max: 9999.99
Current: No Debt

2470.88
9999.99
F-Score: 5
Z-Score: -8.79
M-Score: -2.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -124.20
TEAR's Operating margin (%) is ranked higher than
57% of the 247 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. TEAR: -124.20 )
TEAR' s 10-Year Operating margin (%) Range
Min: -42533.98   Max: 45657.61
Current: -124.2

-42533.98
45657.61
Net-margin (%) -111.00
TEAR's Net-margin (%) is ranked higher than
58% of the 247 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.07 vs. TEAR: -111.00 )
TEAR' s 10-Year Net-margin (%) Range
Min: -74064.13   Max: -197.95
Current: -111

-74064.13
-197.95
ROE (%) -56.00
TEAR's ROE (%) is ranked higher than
55% of the 225 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. TEAR: -56.00 )
TEAR' s 10-Year ROE (%) Range
Min: -203.04   Max: -15.27
Current: -56

-203.04
-15.27
ROA (%) -46.29
TEAR's ROA (%) is ranked higher than
58% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. TEAR: -46.29 )
TEAR' s 10-Year ROA (%) Range
Min: -715.24   Max: -14.38
Current: -46.29

-715.24
-14.38
ROC (Joel Greenblatt) (%) -562.78
TEAR's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. TEAR: -562.78 )
TEAR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8276.17   Max: 4208.92
Current: -562.78

-8276.17
4208.92
Revenue Growth (%) 58.70
TEAR's Revenue Growth (%) is ranked higher than
99% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. TEAR: 58.70 )
TEAR' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 58.7
Current: 58.7

0
58.7
EBITDA Growth (%) 33.50
TEAR's EBITDA Growth (%) is ranked higher than
95% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. TEAR: 33.50 )
TEAR' s 10-Year EBITDA Growth (%) Range
Min: -78   Max: 97.6
Current: 33.5

-78
97.6
EPS Growth (%) 26.00
TEAR's EPS Growth (%) is ranked higher than
91% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.50 vs. TEAR: 26.00 )
TEAR' s 10-Year EPS Growth (%) Range
Min: -78.6   Max: 71.6
Current: 26

-78.6
71.6
» TEAR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

TEAR Guru Trades in Q4 2013

Chuck Royce 488,229 sh (+7649.67%)
» More
Q1 2014

TEAR Guru Trades in Q1 2014

Chuck Royce 1,046,731 sh (+114.39%)
» More
Q2 2014

TEAR Guru Trades in Q2 2014

Chuck Royce 100,000 sh (-90.45%)
» More
Q3 2014

TEAR Guru Trades in Q3 2014

Chuck Royce 100,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with TEAR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.07
TEAR's P/B is ranked higher than
78% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.45 vs. TEAR: 3.07 )
TEAR' s 10-Year P/B Range
Min: 0.18   Max: 63.48
Current: 3.07

0.18
63.48
P/S 4.91
TEAR's P/S is ranked higher than
69% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. TEAR: 4.91 )
TEAR' s 10-Year P/S Range
Min: 4.16   Max: 416.67
Current: 4.91

4.16
416.67
EV-to-EBIT -2.93
TEAR's EV-to-EBIT is ranked lower than
53% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TEAR: -2.93 )
TEAR' s 10-Year EV-to-EBIT Range
Min: -27.1   Max: 0.4
Current: -2.93

-27.1
0.4
Current Ratio 4.61
TEAR's Current Ratio is ranked higher than
85% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.55 vs. TEAR: 4.61 )
TEAR' s 10-Year Current Ratio Range
Min: 0.19   Max: 20.62
Current: 4.61

0.19
20.62
Quick Ratio 4.03
TEAR's Quick Ratio is ranked higher than
84% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.12 vs. TEAR: 4.03 )
TEAR' s 10-Year Quick Ratio Range
Min: 0.14   Max: 19.15
Current: 4.03

0.14
19.15

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.42
TEAR's Price/Net Cash is ranked higher than
93% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TEAR: 6.42 )
TEAR' s 10-Year Price/Net Cash Range
Min: 3.08   Max: 22.78
Current: 6.42

3.08
22.78
Price/Net Current Asset Value 5.02
TEAR's Price/Net Current Asset Value is ranked higher than
94% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TEAR: 5.02 )
TEAR' s 10-Year Price/Net Current Asset Value Range
Min: 3.02   Max: 275
Current: 5.02

3.02
275
Price/Tangible Book 3.53
TEAR's Price/Tangible Book is ranked higher than
84% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.49 vs. TEAR: 3.53 )
TEAR' s 10-Year Price/Tangible Book Range
Min: 2.93   Max: 179.35
Current: 3.53

2.93
179.35
Price/Median PS Value 0.14
TEAR's Price/Median PS Value is ranked higher than
99% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.34 vs. TEAR: 0.14 )
TEAR' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 9.37
Current: 0.14

0.16
9.37
Earnings Yield (Greenblatt) -34.10
TEAR's Earnings Yield (Greenblatt) is ranked lower than
52% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. TEAR: -34.10 )
TEAR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 256.6   Max: 2535
Current: -34.1

256.6
2535
Forward Rate of Return (Yacktman) 5.81
TEAR's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. TEAR: 5.81 )
TEAR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1093.9   Max: 8.5
Current: 5.81

-1093.9
8.5

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:TLB.Canada, OCV1.Germany
TearLab Corp was incorporated as OccuLogix, Inc. in Delaware in 2002. The Company is an in-vitro diagnostic company based in San Diego, California. The Company is commercializing a proprietary tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company's first product measures tear film osmolarity for the diagnosis of Dry Eye Disease, or DED. TearLab Research, Inc. its wholly-owned subsidiary, develops technologies to enable eye care practitioners to test biomarkers (chemistries, metabolites (i.e. glucose), genes and proteins) at the point-of-care. The Company's first product, the TearLab Osmolarity System, enables the rapid measurement of tear osmolarity in the doctor's office. Osmolarity is a quantitative and specific biomarker that has been shown to assist in the diagnosis and disease management of DED. The innovation of the TearLab Osmolarity System is its ability to precisely and rapidly measure osmolarity in nanoliter volumes of tear samples, using an efficient and novel tear collection system at the point of care. The TearLab Osmolarity System consists of the following three components: the TearLab disposable, which is a single-use microfluidic microchip; the TearLab Pen, which is a hand-held device that interfaces with the TearLab disposable; and the TearLab Reader, which is a small desktop unit that allows for the docking of the TearLab Pen and provides a quantitative reading for the operator. The Company relies on two suppliers based in the United States for the manufacture of the Readers and Pens which are key components of the TearLab Osmolarity System. It also relies on a single supplier, MiniFAB (Aust) Pty Ltd. located in Australia, for the manufacture of the test cards which is also a key component of the TearLab Osmolarity System. The Company has licensed multiple patents including eight issued U.S. patents; relating to the TearLab Osmolarity System, three pending U.S. patent applications; eighteen pending patent application countries/regions other than the United States, including six applications in Europe, four applications in Japan, three applications in Canada, two in Australia, one application in Brazil and two applications in Mexico. It has registered the TearLab trademark in the United States, the European Union, Japan, Korea, Mexico, the Russian Federation and Turkey. Its TearLab trademark applications are pending in Canada and China. Government authorities in the United States and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, distribution and marketing of its product, which is a medical device.
» More Articles for TEAR

Headlines

Articles On GuruFocus.com
comment on TEAR Mar 06 2013 

More From Other Websites
TEARLAB CORP Financials Nov 15 2014
TearLab to Participate in November Investor Conferences Nov 11 2014
TearLab to Participate in November Investor Conferences Nov 10 2014
10-Q for TearLab Corp. Nov 08 2014
TEARLAB CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 06 2014
Feltl And Company Upgrades TearLab; Shares Down 12% Nov 06 2014
TearLab Corporation Reports Q3-14 Financial Results Nov 06 2014
TearLab Corporation Reports Q3-14 Financial Results Nov 05 2014
TearLab Corporation to Release Q3 2014 Financial Results on November 5, 2014 Oct 22 2014
Julie Speed Joins TearLab as Vice President, Global Marketing Oct 06 2014
TearLab to Participate in BTIG's Inaugural Emerging Technologies in Healthcare Diagnostics Symposium Sep 25 2014
Study Demonstrates Hyperosmolarity of the Ocular Surface May Impact Cataract Surgery Planning Sep 15 2014
TearLab to Participate in Craig-Hallum's 5th Annual Alpha Select Conference Sep 11 2014
TearLab Reports Interim Results From Multi-Center DED Prevalence Study in the UK Sep 04 2014
TEARLAB CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 07 2014
TEARLAB CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Jul 16 2014
TEARLAB CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to... Jun 13 2014
3 Stocks Trading at 52-Week Lows — Is This the Bottom? May 19 2014
TearLab price target lowered to $10 from $15 at Canaccord May 09 2014
TearLab Corporation's (TEAR) CEO Elias Vamvakas on Q1 2014 Results - Earnings Call Transcript May 08 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK